N-Acetyl Semax Peptide: Modified Semax Analog and the Evidence Gap

N-Acetyl Semax is a chemically modified analog of Semax, a synthetic neuropeptide originally derived from a short fragment of adrenocorticotropic hormone. The parent peptide, Semax, has the sequence Met-Glu-His-Phe-Pro-Gly-Pro, which combines the ACTH(4-7) fragment with a stabilizing Pro-Gly-Pro tail. The "N-acetyl" and "amidate" labels you see in product listings refer to two extra chemical modifications: an acetyl group added to the N-terminus and an amide group at the C-terminus. Both changes are intended to slow the enzymes that normally chew up small peptides.

This guide is educational and not medical advice. N-Acetyl Semax is not an approved medicine in the United States. It is sold as a research chemical, and nothing here should be read as a protocol, a dose recommendation, or a claim that the compound is safe or effective in people.

The honest framing matters here. Most of the science people cite when they talk about "N-Acetyl Semax" is not about the acetylated, amidated analog at all. It is about the original Semax peptide, and even that body of work has real limits. For background on the underlying compound, see our guide to Semax. For broader context on how these molecules are studied, see what peptides are and the peptide half-life guide.

N-Acetyl Semax At A Glance

How Semax Is Thought To Work

The mechanism story for this family starts with adrenocorticotropic hormone, or ACTH. A short internal sequence of ACTH, the (4-10) region, carries effects on memory, attention, and adaptation without the cortisol-stimulating activity of the full hormone. Soviet and later Russian researchers built Semax around the ACTH(4-7) portion of that fragment and attached a Pro-Gly-Pro tripeptide to the end. The Pro-Gly-Pro tail was added specifically to slow enzymatic degradation, extending the molecule's useful window from minutes toward something longer.

In rat experiments, Semax binds in brain tissue in a specific, saturable, reversible way. Dolotov and colleagues reported a dissociation constant in the low nanomolar range and showed that intranasal Semax raised brain-derived neurotrophic factor, or BDNF, in the basal forebrain within hours. BDNF is a growth factor central to neuronal survival and synaptic plasticity, signaling through the TrkB receptor and downstream cascades such as MAPK/ERK and PI3K/Akt.

Later transcriptional studies expanded the picture. Dmitrieva and colleagues found that Semax, and its Pro-Gly-Pro fragment, activated transcription of neurotrophins and their receptor genes after experimental cerebral ischemia, with Semax raising BDNF, TrkC, and TrkA at three hours and NGF and NT-3 later. Genome-wide analyses in the rat middle cerebral artery occlusion model reported that Semax suppressed inflammatory and immune-system genes while activating neurotransmitter-related genes, and protein-level work has been used to argue for a protective effect in ischemia-reperfusion.

The N-acetyl and amide modifications do not change this proposed biology in any documented way. They are stability tweaks. The reasonable assumption is that the analog acts on the same pathways as Semax, but that assumption has not been tested head-to-head in published, peer-reviewed work.

What The Evidence Actually Supports

This is where it pays to separate the parent peptide from the analog.

For Semax, the strongest evidence is preclinical. Multiple rodent studies, several of them open-access, document neurotrophin changes and gene-expression shifts in stroke models. Human work exists but is thinner. Russian groups led by Gusev, Skvortsova, and colleagues reported that adding Semax to standard care in acute ischemic stroke was associated with faster regression of neurological deficits. A 2018 report in 110 patients described elevated plasma BDNF and improved Barthel index and motor scores. Separate resting-state fMRI studies in healthy volunteers reported changes in default mode network and functional connectivity measures after Semax.

These human studies share important weaknesses. Many are small, non-randomized, or open-label. Several are published only in Russian-language journals, where abstracts often omit effect sizes, confidence intervals, and p-values. There are no published Phase 3 trials outside Russia and post-Soviet states. That does not make the findings worthless, but it does mean the human evidence base is weak by the standards used to approve drugs in the United States or Europe.

For N-Acetyl Semax specifically, the situation is starker: there is no dedicated body of peer-reviewed human or animal research on the acetylated, amidated analog. Vendor pages frequently cite an "extended half-life" of several hours and a defined nasal bioavailability, but those numbers do not trace back to any controlled pharmacokinetic study you can verify. Even for parent Semax, the measured plasma half-life is short, on the order of minutes, with rapid aminopeptidase degradation. Any claim that the analog reliably lasts "4 to 6 hours" in humans should be treated as a marketing figure, not a measured one.

If you want to compare this honesty gap with other cognition-focused compounds, see Selank, Cerebrolysin, and Dihexa. Each sits at a different point on the spectrum from "registered drug somewhere" to "almost entirely preclinical."

Safety: What We Know And Do Not Know

Russian labeling for parent Semax presents it as well tolerated, with the selling point that the ACTH(4-7) design avoids the steroidogenic, cortisol- raising activity of full ACTH. But absence of reported problems in small, short, often unblinded studies is not the same as a demonstrated safety profile. For the N-acetylated analog, there is no published toxicology, no reproductive- safety data, and no long-term human follow-up at all.

Because the compound is unapproved, there is also no quality-controlled formulation, no standardized concentration, and no clinician oversight built in. General handling concepts in how to inject peptides safely do not resolve any of these problems, and Semax-family peptides are typically used intranasally rather than injected in the first place.

How To Evaluate An N-Acetyl Semax Claim

When you read a strong claim about this peptide, run it through a few checks.

First, ask whether the cited study is about the analog or about parent Semax. Most "N-Acetyl Semax" benefit claims silently borrow Semax data.

Second, ask whether the study is human or rodent. The mechanistic BDNF and gene-expression findings are mostly in rats, and rodent neuroprotection does not automatically transfer to human cognition.

Third, ask whether human studies are randomized and blinded, and whether they report actual numbers. A lot of the Semax human literature does not.

Fourth, be skeptical of any precise pharmacokinetic figure for the analog. If a source states a clean half-life or bioavailability percentage without a citation to a controlled study, treat it as unverified.

Fifth, watch for the regulatory sleight of hand where "approved in Russia" is used to imply general legitimacy. Russian registration is real, but it is not FDA approval, and it does not cover the acetylated analog at all.

Bottom Line

N-Acetyl Semax is best understood as a chemically tweaked, research-only version of Semax, an ACTH(4-7)-derived neuropeptide with a genuinely interesting preclinical mechanism centered on BDNF and other neurotrophins. The parent peptide has registration in Russia and a real, if modest and methodologically limited, human literature in stroke and cognition. The analog itself has almost none of its own evidence.

That asymmetry is the whole story. The proposed biology is plausible and partly documented in animals. The human benefit claims are weak, the analog-specific data are effectively absent, and the popular pharmacokinetic figures are not traceable to controlled studies. N-Acetyl Semax is not an approved treatment, its safety in people has not been established, and any decision about it belongs with a qualified clinician rather than a product page.

References

1. Dolotov OV, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry, 2006.

2. Dmitrieva VG, et al. Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Cerebral Ischemia. Cellular and Molecular Neurobiology.

3. Medvedeva EV, et al. Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion. International Journal of Molecular Sciences, 2021.

4. Filippenkov IB, et al. Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. PMC.

5. Dergunova LV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics.

6. Medvedeva EV, et al. Effects of Semax on the Default Mode Network of the Brain. PubMed, 2018.

7. Functional Connectomic Approach to Studying Selank and Semax Effects. PubMed, 2020.

8. Gusev EI, et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zhurnal Nevrologii i Psikhiatrii, 1997.

9. Gusev EI, et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii, 2018.

10. Shevchenko KV, et al. Degradation of the ACTH(4-10) analog Semax in the presence of rat basal forebrain cell cultures and plasma membranes. Amino Acids, 2006.